StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Research analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.38 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $71.60 million, a PE ratio of -0.01 and a beta of 2.02. The stock has a 50-day moving average of $0.28 and a 200-day moving average of $0.28. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $12.48.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, equities research analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.